GlassScriptPhysician profile
Katelyn Elizabeth Bone
NPI 1841871423
$2,190.62
in general payments reported to CMS, 2019-2025
26 companies · $610 in 2025
The $610 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $258 · 2022: $366 · 2023: $614 · 2024: $342 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.37 |
| Education | $219.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $307.07 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $270.92 | 2022-2025 | Libtayo |
| Janssen Biotech, INC. | $244.59 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $149.86 | 2025 | Enhertu, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $138.37 | 2023 | Trintellix |
| Merck Sharp & Dohme LLC | $129.51 | 2023-2025 | Keytruda |
| Eisai INC. | $121.97 | 2022-2024 | |
| Mirati Therapeutics, INC. | $112.48 | 2023 | Krazati |
| Helsinn Therapeutics (U.S.), INC. | $104.32 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.38 | 2022 | |
| Abbvie INC. | $101.32 | 2024 | |
| Incyte Corporation | $66.91 | 2022-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $49.93 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.64 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $34.77 | 2022-2023 | Somatuline Depot, Onivyde |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $34.17 | 2025 | Brukinsa |
| Gilead Sciences, INC. | $24.96 | 2023 | Trodelvy |
| Genmab U.S., INC. | $21.71 | 2024 | Epkinly |
| Taiho Oncology, INC. | $20.53 | 2025 | |
| Array Biopharma INC | $20.26 | 2021 | |
| Amgen INC. | $18.94 | 2023 | Lumakras |
| Sobi, INC | $17.89 | 2025 | |
| Beigene USA, INC. | $15.79 | 2023 | Brukinsa |
| Blueprint Medicines Corporation | $15.39 | 2022 | |
| Glaxosmithkline, LLC. | $14.76 | 2023 | Trelegy Ellipta, Shingrix |
| Myriad Genetic Laboratories, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Bone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.